EMA Application withdrawn: Orblid (bevacizumab) — Laboratoires Delbert

View source ↗

Summary

The EMA has withdrawn the application for Orblid (bevacizumab) by Laboratoires Delbert for hereditary telangiectasia/hemorrhagic conditions.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hereditary Hemorrhagic Telangiectasia

Drugs mentioned

• Orblid (bevacizumab)

Snippet

Status: Application withdrawn. Therapeutic area: Telangiectasia, Hereditary Hemorrhagic. MAH: Laboratoires Delbert. Orphan medicine